26.06.2014 | permalink
Monsanto said its earnings fell more than 5 percent in the third fiscal quarter on lower sales of biotech seeds, but its performance still topped Wall Street estimates and the company raised its 2014 outlook. It also announced plans to repurchase $10 billion in shares.
